Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses RZLT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RZLT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Nevan Charles Elam | $610,825 | $451,662 | $1,767,204 | $0 | $0 | $0 | $21,418 | $2,851,109 |
| Chief Executive Officer | ||||||||
| Daron Evans | 421,458 | 231,112 | 1,016,452 | 0 | 0 | 0 | 46,639 | 1,715,661 |
| Chief Financial Officer | ||||||||
| Brian Roberts | 483,361 | 221,988 | 667,202 | 0 | 0 | 0 | 62,177 | 1,434,728 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Nevan Charles Elam | $2,851,109 | $1,192,700 | — | +1,658,409 |
| Daron Evans | 1,715,661 | 384,065 | — | +1,331,596 |
| Brian Roberts | 1,434,728 | 817,959 | — | +616,769 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Erik Harris | Director | 2025-11-19 | A | 21,000 | $0 | $0 | Common | Form 4 ↗ |
| Nerissa Kreher | Director | 2025-11-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wladimir Hogenhuis | Director | 2025-11-19 | A | 21,000 | 0 | 0 | Common | Form 4 ↗ |
| Wladimir Hogenhuis | Director | 2025-11-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Philippe Fauchet | Director | 2025-11-19 | A | 21,000 | 0 | 0 | Common | Form 4 ↗ |
| Gil Labrucherie | Director | 2025-11-19 | A | 21,000 | 0 | 0 | Common | Form 4 ↗ |
| Nevan Charles Elam | Director | 2025-11-19 | A | 186,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Philippe Fauchet | Director | 2025-11-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nevan Charles Elam | Director | 2025-11-19 | A | 317,000 | 0 | 0 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2025-11-19 | A | 107,000 | 0 | 0 | Common | Form 4 ↗ |
| Gil Labrucherie | Director | 2025-11-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Erik Harris | Director | 2025-11-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Young-Jin Kim | Director | 2025-11-19 | A | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Young-Jin Kim | Director | 2025-11-19 | A | 21,000 | 0 | 0 | Common | Form 4 ↗ |
| Brian Roberts | Chief Medical Officer | 2025-11-19 | A | 123,000 | 0 | 0 | Common | Form 4 ↗ |
| Brian Roberts | Chief Medical Officer | 2025-11-19 | A | 72,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sunil Ratilal Karnawat | Chief Commercial Officer | 2025-11-19 | A | 32,000 | 0 | 0 | Common | Form 4 ↗ |
| Sunil Ratilal Karnawat | Chief Commercial Officer | 2025-11-19 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daron Evans | CFO | 2025-11-19 | A | 63,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nerissa Kreher | Director | 2025-11-19 | A | 21,000 | 0 | 0 | Common | Form 4 ↗ |
| Sunil Ratilal Karnawat | Chief Commercial Officer | 2025-12-15 | A | 100 | 2 | 160 | Common | Form 4 ↗ |
| Sunil Ratilal Karnawat | Chief Commercial Officer | 2025-12-15 | A | 12,000 | 2 | 19,439 | Common | Form 4 ↗ |
| Nevan Charles Elam | Director | 2025-12-15 | A | 32,000 | 2 | 50,880 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2025-12-15 | A | 40,000 | 2 | 70,640 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2025-12-15 | A | 2,500 | 2 | 4,463 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2025-12-15 | A | 2,500 | 2 | 4,475 | Common | Form 4 ↗ |
| Wladimir Hogenhuis | Director | 2025-12-16 | A | 5,650 | 2 | 9,549 | Common | Form 4 ↗ |
| Brian Roberts | Chief Medical Officer | 2025-12-16 | A | 28,000 | 2 | 47,600 | Common | Form 4 ↗ |
| Brian Roberts | Chief Medical Officer | 2026-03-02 | D | 11,439 | 3 | 34,203 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2026-03-02 | D | 11,438 | 3 | 34,200 | Common | Form 4 ↗ |
| Nevan Charles Elam | Director | 2026-03-02 | D | 27,618 | 3 | 82,578 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2026-03-30 | A | 10,000 | 3 | 28,500 | Common | Form 4 ↗ |
| Nevan Charles Elam | Director | 2026-07-02 | D | 8,004 | 5 | 39,940 | Common | Form 4 ↗ |
| Daron Evans | CFO | 2026-07-02 | D | 3,062 | 5 | 15,279 | Common | Form 4 ↗ |
| Brian Roberts | Chief Medical Officer | 2026-07-02 | D | 3,062 | 5 | 15,279 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Brian Roberts | RSU | — | — | — | — | — | $667,202 |
| Daron Evans | RSU | — | — | — | — | — | 1,016,452 |
| Nevan Charles Elam | RSU | — | — | — | — | — | 1,767,204 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Brian Roberts | $667,202 | $0 | $0 | 0.0% |
| Daron Evans | 1,016,452 | 0 | 0 | 0.0% |
| Nevan Charles Elam | 1,767,204 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Nevan Charles Elam | RSU | 272,000 | — | $1,213,120 |
| Daron Evans | RSU | 77,000 | — | 343,420 |
| Nevan Charles Elam | RSU | 204,000 | — | 909,840 |
| Brian Roberts | RSU | 26,000 | — | 115,960 |
| Brian Roberts | RSU | 77,000 | — | 343,420 |
| Daron Evans | Option | 40,000 | 4.61 | — |
| Brian Roberts | RSU | 103,000 | — | 459,380 |
| Daron Evans | RSU | 102,395 | — | 332,605 |
| Nevan Charles Elam | RSU | 68,000 | — | 303,280 |
| Daron Evans | RSU | 26,000 | — | 115,960 |
| Nevan Charles Elam | Option | 650,000 | 3.4 | — |
| Nevan Charles Elam | Option | 106,667 | 4.61 | — |
| Brian Roberts | Option | 175,000 | 3.4 | — |
| Brian Roberts | Option | 15,000 | 4.39 | — |
| Daron Evans | Option | 100,000 | 4.79 | — |
| Brian Roberts | Option | 40,000 | 4.61 | — |
| Daron Evans | Option | 15,000 | 4.39 | — |
| Brian Roberts | RSU | 706,388 | — | 3,150,490 |
| Daron Evans | Option | 177,605 | 1.02 | — |
| Nevan Charles Elam | Option | 179,445 | 1.02 | — |
| Nevan Charles Elam | Option | 40,000 | 4.39 | — |
| Daron Evans | RSU | 103,000 | — | 459,380 |
| Brian Roberts | Option | 68,612 | 1.02 | — |
| Nevan Charles Elam | RSU | 2,698,888 | — | 12,037,040 |
The Company's executive compensation program is designed to attract and retain qualified executives through a combination of base salary, annual cash bonuses tied to achievement of performance criteria set by the Board, and equity awards, with target bonus percentages varying by role (e.g., CEO up to 60% of base salary).
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Gil LabrucherieIndependent · Audit (Chair) · Compensation · Nominating/Governance | $74,000 | $157,065 | $65,093 | — | $0 | $296,158 |
| Wladimir HogenhuisIndependent · Audit · Compensation (Chair) · Nominating/Governance | 71,500 | 157,065 | 65,093 | — | 0 | 293,658 |
| Philippe FauchetIndependent · Audit · Compensation · Nominating/Governance | 67,500 | 157,065 | 65,093 | — | 0 | 289,658 |
| Nerissa KreherIndependent · Nominating/Governance (Chair) · Compensation | 63,000 | 157,065 | 65,093 | — | 0 | 285,158 |
| Young-Jin KimNot independent | 45,000 | 157,065 | 65,093 | — | 0 | 267,158 |
| Erik HarrisIndependent · Compensation · Newly elected | 11,250 | 0 | 125,670 | — | 0 | 136,920 |
| Nevan Charles ElamEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 11,000 / 11,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $332,250 |
| Equity awards (grant-date value) | $785,325 |
| All other compensation | $0 |
| Total cost of the board | $1,117,575 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Rezolute | 2025 | Nevan Charles Elam | $610,825 | $1,767,204 | $0 | $0 | $2,851,109 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Nevan Charles Elam | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Summary Compensation Table”. As printed: 2,851,109. Filing ↗machine: t83 · r3 · c17 · span 413905–413914 |
| 2 | Section 01, Daron Evans | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Summary Compensation Table”. As printed: 1,715,661. Filing ↗machine: t83 · r7 · c17 · span 433110–433119 |
| 3 | Section 01, Brian Roberts | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Summary Compensation Table”. As printed: 1,434,728. Filing ↗machine: t83 · r5 · c17 · span 423497–423506 |
| 4 | Section 03, Brian Roberts RSU | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t83 · r5 · c11 · span 421763–421770 |
| 5 | Section 03, Daron Evans RSU | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t83 · r7 · c11 · span 431373–431382 |
| 6 | Section 03, Nevan Charles Elam RSU | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t83 · r3 · c11 · span 412169–412178 |
| 7 | Section 07, pay ratio | 10-K | 2025-09-17 | 0001104659-25-090848 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, Gil Labrucherie | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Director Compensation”. As printed: 296,158. Filing ↗machine: t41 · r5 · c8 · span 201203–201210 |
| 9 | Section 08, Wladimir Hogenhuis | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Director Compensation”. As printed: 293,658. Filing ↗machine: t41 · r8 · c8 · span 209195–209202 |
| 10 | Section 08, Philippe Fauchet | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Director Compensation”. As printed: 289,658. Filing ↗machine: t41 · r7 · c8 · span 206472–206479 |
| 11 | Section 08, Nerissa Kreher | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Director Compensation”. As printed: 285,158. Filing ↗machine: t41 · r6 · c8 · span 203922–203929 |
| 12 | Section 08, Young-Jin Kim | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Director Compensation”. As printed: 267,158. Filing ↗machine: t41 · r9 · c8 · span 211742–211749 |
| 13 | Section 08, Erik Harris | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Director Compensation”. As printed: 136,920. Filing ↗machine: t41 · r4 · c8 · span 198654–198661 |
| 14 | Section 08, Nevan Charles Elam | DEF 14A | 2025-10-07 | 0001104659-25-097509 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 15 | Section 02, Erik Harris 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001286 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Nerissa Kreher 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001290 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Wladimir Hogenhuis 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001288 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Wladimir Hogenhuis 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001288 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Philippe Fauchet 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001281 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Gil Labrucherie 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001279 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Nevan Charles Elam 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001294 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Philippe Fauchet 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001281 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Nevan Charles Elam 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001294 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Daron Evans 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001292 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Gil Labrucherie 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001279 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Erik Harris 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001286 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Young-Jin Kim 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001283 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Young-Jin Kim 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001283 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Brian Roberts 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001299 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Brian Roberts 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001299 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Sunil Ratilal Karnawat 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001298 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Sunil Ratilal Karnawat 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001298 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Daron Evans 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001292 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Nerissa Kreher 2025-11-19 | Form 4 | 2025-11-21 | 0000912282-25-001290 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Sunil Ratilal Karnawat 2025-12-15 | Form 4 | 2025-12-15 | 0000912282-25-001421 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Sunil Ratilal Karnawat 2025-12-15 | Form 4 | 2025-12-15 | 0000912282-25-001421 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Nevan Charles Elam 2025-12-15 | Form 4 | 2025-12-15 | 0000912282-25-001423 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Daron Evans 2025-12-15 | Form 4 | 2025-12-15 | 0000912282-25-001424 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Daron Evans 2025-12-15 | Form 4 | 2025-12-15 | 0000912282-25-001424 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Daron Evans 2025-12-15 | Form 4 | 2025-12-15 | 0000912282-25-001424 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Wladimir Hogenhuis 2025-12-16 | Form 4 | 2025-12-17 | 0000912282-25-001429 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Brian Roberts 2025-12-16 | Form 4 | 2025-12-17 | 0000912282-25-001427 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Brian Roberts 2026-03-02 | Form 4 | 2026-03-04 | 0000912282-26-000412 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Daron Evans 2026-03-02 | Form 4 | 2026-03-04 | 0000912282-26-000411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Nevan Charles Elam 2026-03-02 | Form 4 | 2026-03-04 | 0000912282-26-000410 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Daron Evans 2026-03-30 | Form 4 | 2026-03-31 | 0000912282-26-000533 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Nevan Charles Elam 2026-07-02 | Form 4 | 2026-07-07 | 0000912282-26-000930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Daron Evans 2026-07-02 | Form 4 | 2026-07-07 | 0000912282-26-000929 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Brian Roberts 2026-07-02 | Form 4 | 2026-07-07 | 0000912282-26-000936 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 51 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 52 | Section 09b board cost (computed) | Computed | — | computed | Cash 332,250 + equity 785,325 + all other 0 = 1,117,575, summed across the director compensation table rows.machine: formula: Σ = 1,117,575 |
| 53 | Rezolute (subject), Section 10b CEO total | DEF 14A | 2025-10-07 | 0001104659-25-097509 | CEO total compensation as printed in Rezolute's own proxy. As printed: 2,851,109. Filing ↗machine: t83 · r3 · c17 · span 413905–413914 |